Eris Lifesciences Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1371 as of 06 May 15:30 . The P/E Ratio of ERIS Lifesciences Ltd changed from 23.1 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 18.86% over 5 yearsThe P/E Ratio of Novartis India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of ERIS Lifesciences Ltd changed from ₹ 8207 crore on March 2021 to ₹ 19287 crore on March 2025 . This represents a CAGR of 18.64% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of ERIS Lifesciences Ltd for the Dec '25 is ₹ 807.59 crore as compare to the Sep '25 revenue of ₹ 795.5 crore. This represent the growth of 1.52% The revenue of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of ERIS Lifesciences Ltd for the Dec '25 is ₹ 264.51 crore as compare to the Sep '25 ebitda of ₹ 291.3 crore. This represent the decline of -9.2% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 108.83 crore over 7 quarters. This represents a CAGR of 11.79% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of ERIS Lifesciences Ltd changed from 21.3 % on March 2021 to 129.35 % on March 2025 . This represents a CAGR of 43.44% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of ERIS Lifesciences Ltd and Novartis India Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Novartis India Ltd?

Market cap of ERIS Lifesciences Ltd is 19,001 Cr while Market cap of Novartis India Ltd is 2,594 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Novartis India Ltd?

The stock performance of ERIS Lifesciences Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Novartis India Ltd?

As of May 6, 2026, the ERIS Lifesciences Ltd stock price is INR ₹1371.5. On the other hand, Novartis India Ltd stock price is INR ₹1050.7.

How do dividend payouts of ERIS Lifesciences Ltd and Novartis India Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.